|
|
|
|
| LEADER |
01442nam a2200277 u 4500 |
| 001 |
EB001839986 |
| 003 |
EBX01000000000000001003975 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
180702 r ||| eng |
| 245 |
0 |
0 |
|a Omega-3 fatty acids for proteinuria due to nephrotic syndrome
|h Elektronische Ressource
|b a review of clinical effectiveness and cost-effectiveness
|c prepared by Canadian Agency for Drugs and Technologies in Health
|
| 260 |
|
|
|a Ottawa (ON)
|b CADTH Rapid Response Service
|c 2016, 05 February 2016
|
| 300 |
|
|
|a 1 PDF file (29 pages)
|b illustration
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 653 |
|
|
|a Proteinuria / therapy
|
| 653 |
|
|
|a Nephrotic Syndrome / therapy
|
| 653 |
|
|
|a Treatment Outcome
|
| 653 |
|
|
|a Fatty Acids, Omega-3 / therapeutic use
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|b Rapid Response Service
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a Rapid response report: summary with critical appraisal
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK350633
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a The purpose of this review is to assess the clinical and cost-effectiveness of n-3 fatty acid supplementation for the reduction of proteinuria in patients with nephrotic syndrome
|